



Contact: Adam D. Gridley
Vice President of Corporate Development
Phone: 650.286.4000

RADIESSE™ NASOLABIAL FOLD TREATMENT MULTICENTER STUDY SUPPORTS FILING FOR U.S. AESTHETIC APPROVAL

Radiesse is a New Filler Designed to Provide a Longer Term Augmentation than Current Products

San Mateo, CA – November 8, 2005. BioForm Medical, Inc., the manufacturer of Radiesse, a longer-lasting injectable filler, announced today positive results from a multi-center, pivotal study using Radiesse for the treatment of nasolabial folds, sometimes referred to as smile lines. These successful clinical trial results will be the cornerstone of the Company's submission to the U.S. Food and Drug Administration (FDA) of a pre-market approval (PMA) application to market Radiesse for additional facial aesthetics applications.

“We are very pleased that Radiesse demonstrated long-lasting improvement in the appearance of nasolabial folds in patients treated in this pivotal study. These results allow us to move forward seeking FDA clearance for facial aesthetic applications.” said Steven L. Basta, President and CEO of BioForm. “Radiesse is the first injectable filler that has proven benefit in two multi-center U.S. studies in facial aesthetics. The results observed with Radiesse in this study were more durable than one of the commonly used short term fillers, demonstrating that Radiesse may provide physicians and patients with a longer-term option for treatment.”

Initial findings of this pivotal clinical study were presented last week by Mariano Busso, M.D., Miami, FL, one of the study investigators, at the American Society for Dermatologic Surgery (ASDS) meeting in Atlanta, GA.

Results were based on 117 patients treated at four clinical sites in the U.S. All study patients were randomized, with each patient receiving injections of Radiesse in one side of their face and human collagen, Cosmoplast® (manufactured by Inamed Aesthetics), on the other side. Evaluation of the nasolabial folds in these patients was conducted by three, independent, blinded evaluators.

Key Clinical Results

The key findings of the study were as follows:

- 82% of nasolabial folds treated with Radiesse showed improvement at six months. This was significantly higher than the control agent, which showed improvement in only 27% of treated folds (p<0.0001).
- At six months, the fold treated with Radiesse was more improved in 79% of patients compared to the collagen treated fold. In only 5% of patients were the folds treated with the control agent rated more improved than the folds treated with Radiesse (p<0.0001).

- The nasolabial folds treated with Radiesse received only half as much Radiesse (1.22cc) as the volume of collagen (2.35cc) required to treat the other side.

This multi-center study was conducted by BioForm under an Investigational Device Exemption (IDE) granted by the FDA. BioForm is preparing to submit the nasolabial fold study results to the FDA. In September 2005, BioForm submitted a PMA for Radiesse based on results from a recently completed facial lipoatrophy study of 100 patients that demonstrated 100% of patients improved through 12 months.

About Radiesse

Manufactured and distributed worldwide by BioForm Medical, Inc., Radiesse is an injectable filler used in various cosmetic, reconstructive and therapeutic applications to augment and contour folds, depressions and defects of the facial area. Radiesse is marketed outside of the U.S. for facial soft tissue augmentation and vocal fold augmentation (VFA) and is approved in the U.S. for VFA and maxillofacial augmentation. Composed of smooth calcium hydroxylapatite (CaHA) particles suspended in a gel carrier, Radiesse has been demonstrated to be safe and biocompatible in numerous soft tissue applications. It has been used in more than 150,000 procedures worldwide with an excellent safety record. Among the product's many advantages, Radiesse treatment allows steady growth of collagen matrix around the particles, produces immediate results, and is intended to last one to three years.

About BioForm Medical, Inc.

BioForm Medical, Inc. is a privately-held medical device company developing and commercializing injectable implant products for soft tissue augmentation. Radiesse™ and Coaptite® have an extensive record of safe clinical use in a variety of applications. BioForm has recently completed two clinical trials evaluating Radiesse for nasolabial folds and facial lipoatrophy in the U.S., and has initiated the PMA process with the FDA for these indications. Coaptite is sold outside of the U.S. to treat female stress urinary incontinence (SUI) and pediatric vesicoureteral reflux and is under PMA review for SUI in the U.S. For more information about BioForm, please visit the www.bioformmedical.com